Progress of next generation sequencing in activated B-cell like diffuse large B-cell lymphoma / 白血病·淋巴瘤

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL), being the most common lymphoma entity, accounting for 30 % ˉ 40 % of newly diagnosed non-Hodgkin lymphomas, is a kind of highly heterogeneous lymphoma with different pathogenesis, clinical manifestations, morphological characteristics, the immune phenotype, molecular subgroup and clinical outcomes. Gene sequencing of DLBCL has redefined the genetic landscape of the disease by identifying recurrent single nucleotide variants, which provides more powerful evidence to support accurate diagnosis and targeted treatment in DLBCL molecular subtypes.